• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Marrone Bio Innovations Bio-Based Pest Management Trials Show Positive Results

October 11, 2017

 

Marrone Bio Innovations, Inc. (NASDAQ:MBII), a developer of bio-based pest management and plant health products for agriculture, turf, water treatment and cannabis markets, released new results of field trials in Brazil that show its products are matching or beating chemical-based pesticides in key crops for pesticide use.

 

“Our biological pesticides yielded excellent results in recent field trials in Brazil. This is an important target market for our products due to bioinsecticides’ high market share and the urgent need for effective pest control solutions,” said Pam Marrone, MBI’s Chief Executive Officer. “I anticipate a clear path to completion of the registration process in Brazil, as the country’s teams of biopesticide regulators review the positive trial results. We look forward to expanding into Brazil and helping growers tackle a wide range of unmet challenges.”

 

As we covered back in June, Marrone Bio Innovations also develops products suitable for cannabis cultivators. While pest management is an important aspect of farming crops like corn and soybeans, it is just as important for marijuana. Since cannabis is often burned or vaporized and then inhaled, using a bio-based pest management solution is far superior to using a chemical-based pesticide. 

 

With substantial short interest in shares of MBII, and an analyst average price target of $2.75, there is potentially over 157% upside in the stock. Piper Jaffray's Brett Wong currently has a 'Hold' rating on MBII, with a price target of $2.00 per share, while H.C. Wainwright's Amit Dayal has a 'Buy' rating on MBII with a price target of $3.50 per share. An older analyst update from 5 months ago (not included in our average analyst PT) shows that Jefferies' Laurence Alexander assigned a 'Hold' rating on MBII with a price target of $2.50. 

 

As more there are more developments for Marrone Bio Innovations, we'll be sure to update readers. MBII is a great example of an ancillary company that stands to gain from widespread legalization of cannabis. Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram

 

D/M/O

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.